{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bisbee C"],"funding":["St. Jude Children&apos;s Research Hospital cancer center support","National Cancer Institute","American Lebanese Syrian Associated Charities","NCI NIH HHS"],"pagination":["459-468"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8957602"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["89(4)"],"pubmed_abstract":["<h4>Purpose</h4>Crenolanib, an oral inhibitor of platelet-derived growth factor receptor, was evaluated to treat children and young adults with brain tumors. Crenolanib population pharmacokinetics and covariate influence were characterized in this patient population.<h4>Methods</h4>Patients enrolled on this phase I study (NCT01393912) received oral crenolanib once daily. Serial single-dose and steady-state serum pharmacokinetic samples were collected and analyzed using a validated LC-ESI-MS/MS method. Population modeling and covariate analysis evaluating demographics, laboratory values, and comedications were performed. The impact of significant covariates on crenolanib exposure was further explored using model simulations.<h4>Results</h4>Crenolanib serum concentrations were analyzed for 5"],"journal":["Cancer chemotherapy and pharmacology"],"pubmed_title":["Population pharmacokinetics of crenolanib in children and young adults with brain tumors."],"pmcid":["PMC8957602"],"funding_grant_id":["P30 CA021765","R25CA23944","R25 CA023944","R01CA154619","CA21765"],"pubmed_authors":["Bisbee C","Campagne O","Gajjar A","Tinkle CL","Stewart CF"],"additional_accession":[]},"is_claimable":false,"name":"Population pharmacokinetics of crenolanib in children and young adults with brain tumors.","description":"<h4>Purpose</h4>Crenolanib, an oral inhibitor of platelet-derived growth factor receptor, was evaluated to treat children and young adults with brain tumors. Crenolanib population pharmacokinetics and covariate influence were characterized in this patient population.<h4>Methods</h4>Patients enrolled on this phase I study (NCT01393912) received oral crenolanib once daily. Serial single-dose and steady-state serum pharmacokinetic samples were collected and analyzed using a validated LC-ESI-MS/MS method. Population modeling and covariate analysis evaluating demographics, laboratory values, and comedications were performed. The impact of significant covariates on crenolanib exposure was further explored using model simulations.<h4>Results</h4>Crenolanib serum concentrations were analyzed for 5","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-26T04:42:58.314Z","creation":"2025-04-06T11:14:56.376Z"},"accession":"S-EPMC8957602","cross_references":{"pubmed":["35212779"],"doi":["10.1007/s00280-022-04412-8"]}}